

PARADIGM BIOPHARMACEUTICALS LIMITED



ASX RELEASE

3rd July 2020

Paradigm adds Dr Donna Skerrett as Executive Director

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to announce the recent appointment of Dr Donna Skerrett to the board as Executive Director. Dr Skerrett is Paradigm's current Chief Medical Officer based in New York and brings to the board significant medical and strategic experience from her more than 30 years in the Pharmaceutical Industry.

Dr Donna Skerrett, Paradigm's Chief Medical Officer and Executive Director

Dr Skerrett joins the Paradigm board with more than three decades of experience in transfusion medicine, cellular therapy and transplantation. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Centre in New York from 2004 to 2011 and served as Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University's New York-Presbyterian Hospital from 1999 to 2004.

Dr Skerrett has been an advisor to the New York State Department of Health on the Progenitor Cell Committee since 1989 and a board member of the Alliance for Regenerative Medicine since 2014. From 2004, she held roles at Mesoblast in clinical and regulatory affairs until she was appointed Chief Medical Officer in 2011. She previously chaired the New York State Council on Blood and Transfusion Services and currently serves on the Board of Directors of the Fox Chase Cancer Centre in Philadelphia and the Board of Visitors of Lewis Katz School of Medicine in Philadelphia. Dr Skerrett holds educational degrees from University of Pennsylvania (BA) Lewis Katz School of Medicine at Temple University (MD) and the Columbia University Mailman School of Public Health (MSc).

Dr Skerrett joined the Paradigm team in September 2019, where she was appointed Chief Medical Officer with her primary role to manage the company's clinical development programs across Paradigm's entire indication pipeline. Dr Skerrett brings a wealth of knowledge to the Paradigm board, with her executive responsibilities to include updates on operations of Paradigm's US entity, oversight of the clinical development programs and strategic development of new opportunities for translation and growth.

Mr. Paul Rennie, Paradigm's CEO and Interim Executive Chairman said:

"I am pleased that Dr Donna Skerrett has agreed to join the Paradigm Board. Donna brings a number of important skills and pharmaceutical development experience to the Board including her strategic thinking, her deep understanding of the US health care system and reimbursement of pharmaceutical products and her extensive experience with regulatory agencies like the US FDA. Donna's clinical trial expertise extends over many projects and she has a proven track record with moving many programs from research projects through clinical and registered pathways".

Authorised for release by Paul Rennie, CEO and Interim Executive Chairman.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com